METOJECT 50 MGML S.C Iżrael - Ingliż - Ministry of Health

metoject 50 mgml s.c

tzamal bio-pharma ltd - methotrexate - solution for injection - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

METOJECT 50 MGML S.C Iżrael - Ingliż - Ministry of Health

metoject 50 mgml s.c

tzamal bio-pharma ltd - methotrexate - solution for injection - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

METOJECT 50 MGML S.C Iżrael - Ingliż - Ministry of Health

metoject 50 mgml s.c

tzamal bio-pharma ltd - methotrexate - solution for injection - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

METOJECT 50 MGML S.C Iżrael - Ingliż - Ministry of Health

metoject 50 mgml s.c

tzamal bio-pharma ltd - methotrexate - solution for injection - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines.

Heparin sodium 1,000 I.U./ml Solution for injection or concentrate for solution for infusion, 5ml vials Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

heparin sodium 1,000 i.u./ml solution for injection or concentrate for solution for infusion, 5ml vials

wockhardt uk limited - heparin sodium - solution injection or concentrate for solution infusion - 1000 international unit(s)/millilitre - heparin group; heparin

Heparin sodium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion, 0.2ml ampoules Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

heparin sodium 25,000 i.u./ml solution for injection or concentrate for solution for infusion, 0.2ml ampoules

wockhardt uk limited - heparin sodium - solution injection or concentrate for solution infusion - 25,000 international unit(s)/millilitre - heparin group; heparin

Heparin sodium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion, 5 ml vials Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

heparin sodium 25,000 i.u./ml solution for injection or concentrate for solution for infusion, 5 ml vials

wockhardt uk limited - heparin sodium - solution injection or concentrate for solution infusion - 25000 international unit(s)/millilitre - heparin group; heparin

Heparin sodium 5,000 I.U./ml Solution for injection or concentrate for solution for infusion, 5 ml vials Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

heparin sodium 5,000 i.u./ml solution for injection or concentrate for solution for infusion, 5 ml vials

wockhardt uk limited - heparin sodium - solution injection or concentrate for solution infusion - 5000 international unit(s)/millilitre - heparin group; heparin

Methotrexate 2.5mg Tablets Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

methotrexate 2.5mg tablets

orion corporation - methotrexate - tablet - 2.5 milligram(s) - other immunosuppressants; methotrexate

Methotrexate 10 mg tablets Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

methotrexate 10 mg tablets

orion corporation - methotrexate - tablet - 10 milligram(s) - other immunosuppressants; methotrexate